· For research use only. Not for human consumption.
For research use only. Not for human consumption.
If you have read anything about Ipamorelin, you have almost certainly seen it described as “selective.” In fact, the original 1998 study that introduced this compound to the scientific world called it “the first selective growth hormone secretagogue.” But what does Ipamorelin selective actually mean? Why is selectivity such a big deal in research? And how does Ipamorelin compare to other, less selective compounds in the same family?
This post answers all of those questions in plain language. You do not need a pharmacology background to understand selectivity. The concept is surprisingly intuitive once it is explained without jargon. By the end, you will know exactly why researchers consider Ipamorelin’s selectivity its most important characteristic. You can view our full range of research compounds at the Alpha Peptides catalog.
Let us start with the basic concept of selectivity and then see how Ipamorelin earned its reputation.
TL;DR: “Selective” means Ipamorelin stimulates growth hormone release without significantly affecting other hormones like cortisol or prolactin. Earlier GHRPs (GHRP-6, GHRP-2) lack this selectivity. Raun et al. (1998) first characterized Ipamorelin as the first selective GH secretagogue (PMID: 9849822). This selectivity makes experimental results cleaner and easier to interpret. For research use only. Not for human consumption.
What “Selective” Means in Pharmacology: Ipamorelin selective Insights
In pharmacology, selectivity describes how precisely a compound hits its intended target without affecting other targets. Think of it like the difference between a flashlight and a laser pointer. A flashlight lights up everything in its path. A laser pointer hits one precise spot and nothing else.
When scientists call a compound “selective,” they mean it does one thing well without creating a bunch of side effects or unrelated changes. When they call a compound “non-selective,” they mean it does its main job but also triggers other responses that the researcher was not aiming for.
In the context of growth hormone secretagogues, selectivity refers specifically to whether a compound causes growth hormone release without simultaneously triggering the release of other hormones. The two hormones that researchers watch most closely in this context are cortisol (a stress hormone produced by the adrenal glands) and prolactin (a hormone involved in multiple biological processes).
A perfectly selective growth hormone secretagogue would increase growth hormone release and nothing else. A non-selective one would increase growth hormone, cortisol, and prolactin all at the same time.
Why Ipamorelin Is Called the First Selective GH Secretagogue
Before Ipamorelin, every Growth Hormone Releasing Peptide (GHRP) that scientists tested came with the same problem: they triggered growth hormone release, but they also triggered noticeable increases in cortisol and prolactin. This was true of GHRP-6 (one of the earliest GHRPs studied) and GHRP-2 (a more potent but similarly non-selective compound).
In 1998, Raun and colleagues published a study that changed the landscape. They characterized Ipamorelin and demonstrated that it stimulated growth hormone release from the pituitary gland without causing significant changes in cortisol or prolactin levels. This was a first. No previous GHRP had achieved this level of specificity.
The title of their paper said it all: Ipamorelin selective growth hormone secretagogue. That single word, “selective,” is what has defined Ipamorelin’s identity in the research community ever since.
Raun K et al. (1998) characterized Ipamorelin as the first selective growth hormone secretagogue, demonstrating GH release without significant effects on cortisol or prolactin in preclinical models. (PMID: 9849822)
Ipamorelin vs GHRP-6: A Selectivity Comparison
To understand why selectivity matters, it helps to compare Ipamorelin selective behavior against a non-selective alternative. GHRP-6 is the most commonly cited comparison.
GHRP-6: When GHRP-6 activates the GHS receptor on pituitary cells, it triggers growth hormone release. But it also causes measurable increases in cortisol and prolactin. In research terms, this creates “confounding variables.” If a researcher sees a change in an experiment after using GHRP-6, they cannot be sure whether that change was caused by the growth hormone increase, the cortisol increase, the prolactin increase, or some combination of all three.
Ipamorelin: When Ipamorelin activates the GHS receptor, it triggers growth hormone release with minimal changes in cortisol and prolactin. This means that if a researcher sees a change in an experiment after using Ipamorelin, they can be much more confident that the change is related to growth hormone specifically.
In research, this kind of clean, interpretable data is extremely valuable. The fewer confounding variables in an experiment, the more reliable the results.
Ipamorelin vs GHRP-2: More Potency, Less Selectivity
GHRP-2 presents a different comparison. It is generally considered more potent than GHRP-6, meaning it can stimulate a larger growth hormone response. However, like GHRP-6, it also affects cortisol and prolactin levels, though the exact profile differs somewhat from GHRP-6.
This illustrates an important trade-off in pharmacology: potency and selectivity are not the same thing. A compound can be very potent (producing a large response) but not selective (affecting multiple targets). Conversely, a compound can be highly selective (affecting only one target) but less potent (producing a smaller total response).
Ipamorelin occupies a unique position because it maintains good growth hormone secretagogue activity while achieving a level of selectivity that GHRP-2 and GHRP-6 do not. For many research applications, this balance of adequate potency plus high selectivity makes Ipamorelin the preferred tool.
What Selectivity Means for Research Quality
Selectivity is not just a nice-to-have feature in a research compound. It has direct implications for the quality and reliability of scientific experiments. Here is why:
Cleaner data. When a compound affects only one target, the researcher can confidently attribute any observed effects to that one target. With non-selective compounds, the results are always ambiguous because multiple hormones changed at the same time.
Better controls. Selective compounds make it easier to design proper control experiments. If the only variable that changed is growth hormone, the experiment is simpler to interpret and the conclusions are stronger.
Reproducibility. Experiments using selective compounds tend to produce more consistent results across different laboratories. When multiple variables change at once (as with non-selective compounds), small differences in experimental conditions can lead to very different results.
Johansen et al. (1999) used Ipamorelin in preclinical research on longitudinal bone growth in rats, demonstrating one application where its selectivity allowed researchers to study growth hormone-related effects without cortisol-related confounding.
Johansen PB et al. (1999) investigated Ipamorelin’s effects on longitudinal bone growth in rats, leveraging the compound’s selectivity for clean experimental data. (PMID: 10373343)
Additional Published Research on Ipamorelin
Beyond the original Raun et al. (1998) characterization, subsequent studies have continued to investigate Ipamorelin’s properties and applications in research settings.
Andersen et al. (2001) examined whether Ipamorelin could counteract glucocorticoid-induced decreases in bone formation markers in preclinical models. Glucocorticoids are a class of steroid hormones that include cortisol, and their effects on bone have been well-documented in scientific literature. By using a selective growth hormone secretagogue like Ipamorelin, the researchers could study growth hormone-related bone effects without the confounding influence that a non-selective compound would introduce through its own cortisol-altering effects.
Andersen NB et al. (2001) investigated Ipamorelin’s ability to counteract glucocorticoid-induced decreases in bone formation in a preclinical model. (PMID: 11735244)
These studies illustrate how Ipamorelin’s selectivity is not just a theoretical advantage but a practical one. It enables types of research that would be harder to conduct with less selective compounds, because the results would be clouded by changes in multiple hormones simultaneously.
The fact that Ipamorelin continues to be used in published research more than 25 years after its initial characterization speaks to how valuable selectivity is in the research tool box. Scientists keep choosing it precisely because it gives them clean, interpretable results.
Alpha Peptides carries Ipamorelin and other growth hormone secretagogues for qualified researchers. Browse our complete catalog to check current availability, and review our Certificates of Analysis (COAs) for purity and identity verification on every batch.
Frequently Asked Questions
What does “selective” mean when describing Ipamorelin?
Selective means Ipamorelin stimulates growth hormone release without significantly increasing other hormones like cortisol or prolactin. This makes it a more precise research tool compared to non-selective growth hormone releasing peptides.
How does Ipamorelin compare to GHRP-6?
Both stimulate growth hormone release through the GHS/ghrelin receptor, but GHRP-6 also causes increases in cortisol and prolactin. Ipamorelin achieves growth hormone release with minimal effects on these other hormones, giving it better selectivity.
Why is selectivity important in research?
Selectivity produces cleaner experimental data. When only one variable changes (growth hormone), researchers can confidently attribute observed effects to that variable. Non-selective compounds change multiple variables at once, making results harder to interpret.
Who first characterized Ipamorelin as selective?
Raun et al. published the original characterization of Ipamorelin in 1998, describing it as the first selective growth hormone secretagogue. The study demonstrated GH release without significant cortisol or prolactin changes in preclinical models.
Is Ipamorelin a GHRH analog or a GHRP?
Ipamorelin is a GHRP (Growth Hormone Releasing Peptide). It binds to the GHS/ghrelin receptor, not the GHRH receptor. This makes it mechanistically different from GHRH analogs like Tesamorelin, which mimic the hypothalamic GHRH signal.
For research use only. Not for human consumption. This material is sold strictly for use in scientific and laboratory research. It is not intended for diagnostic or therapeutic purposes. Alpha Peptides does not endorse or encourage any off-label use.
